


## TP-020

<b>Cat. No.:</b>	HY-101857		
<b>CAS No.:</b>	1800025-30-2		
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>21</sub> ClF <sub>5</sub> N <sub>7</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	654.01		
<b>Target:</b>	Acyltransferase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 125 mg/mL (191.13 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.5290 mL	7.6451 mL	15.2903 mL
	5 mM	0.3058 mL	1.5290 mL	3.0581 mL
	10 mM	0.1529 mL	0.7645 mL	1.5290 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

TP-020 (MGAT2-IN-1) is an orally active inhibitor of monoacylglycerol acyltransferase (MGAT2) with IC<sub>50</sub> of 7.8 and 2.4 nM for human and mouse MGAT2, respectively.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 7.8 nM (Human MGAT2), 2.4 nM (Mouse MGAT2)<sup>[1]</sup>

#### In Vivo

TP-020 (3, 10 mg/kg, p.o.) dose-dependently suppresses plasma TG elevation, and plasma CM/TG AUC in mice. TP-020 does not decrease MG absorption but inhibits MGAT2-dependent TG/DG resynthesis. In the lipid utilization analysis, TP-020 significantly increases free fatty acid (FFA) and acylcarnitine levels. TP-020 (30 mg/kg) also significantly reduces food intake dose dependently, suppresses BW gains. TP-020 shows anti-diabetic effects in mice<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### PROTOCOL

---

**Animal Administration** <sup>[1]</sup>

Mice: Overnight-fasted mice undergo MTT in the morning. First, they are orally administered vehicle (0.5% methylcellulose solution) or MGAT2-IN-1 suspended in 0.5% methylcellulose. Six or 16 h after dosing, they are intraperitoneally injected 500 mg/kg Pluronic F-127 to inhibit plasma TG hydrolysis by lipoprotein lipase (LPL). Thirty minutes after injection, the mice are given an oral liquid meal (10 mL/kg) comprising an admixture of corn oil and Ensure-H (3:17 v/v). Blood samples are collected at 0, 2 and 4 h after oral gavage of the liquid meal. Area under the curve (AUC) of chylomicron TG (CM/TG), which is synthesised from dietary fat in the small intestine, is calculated by subtracting plasma TG levels of a liquid meal-untreated group from plasma TG levels of each treated group.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

**REFERENCES**

[1]. Take K, et al. Pharmacological Inhibition of Monoacylglycerol O-Acyltransferase 2 Improves Hyperlipidemia, Obesity, and Diabetes by Change in Intestinal Fat Utilization. PLoS One. 2016 Mar 3;11(3):e0150976.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA